NKG2D CAR-T Cell

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameNKG2D CAR-T Cell
Drug Alias NameNKG2DL-specific CAR-NK cell therapy (Cheetah Cell Therapeutics)anti-NKG2D CAR T-cell therapy (Cheetah Cell Therapeutics)anti-NKG2DL CAR-NK-cell therapy (Cheetah Cell Therapeutics)anti-NKG2D-ligand CAR-NK-cell therapy (Cheetah Cell Therapeutics)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionNKG2-D type II integral membrane protein modulators
TargetsNKG2-D type II integral membrane protein
Therapy Area/IndicationsNeoplasm MetastasisOvarian NeoplasmsColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHangzhou Cheetah Cell Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Cheetah Cell Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasm MetastasisOvarian NeoplasmsColorectal Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A